State of the Art Biomedical Services
CryoLife, Inc. is one of the world’s leading contemporary medical device companies, providing:
Preserved human cardiac and vascular tissues
Surgical adhesives and sealants
Implantable end-stage renal disease hemodialysis access grafts for vascular reconstruction surgeries
Since the Company’s inception in 1984, it is estimated that its products and tissues have been implanted in over 1,000,000 patients worldwide.
Products & Services
BioGlue Surgical Adhesive™
The leading surgical adhesive used in cardiovascular surgery.
AV access solution to reduce catheter dependency.
ProCol® Vascular Bioprosthesis
A natural biological graft derived from a bovine mesenteric vein that provides vascular access for ESRD hemodialysis patients.
Transmyocardial revascularization (TMR) is a clinically proven laser therapy procedure for chronic angina patients.
Aortic and pulmonary homografts for cardiac reconstruction.
Allografts for AV access, peripheral bypass, and infected fields.
News & Events
CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015
May 21, 2015
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the second quarter 2015 of $0.03 per share of common stock outstanding. The quarterly cash dividend of $0.03 per share will be paid on June 19, 2015 to all common stockholders of record as of June 12, 2015. The ex-dividend date for the quarterly dividend is June 10, 2015.
CryoLife Reports First Quarter Results
April 28, 2015
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2015 first quarter financial results will be released on Tuesday, April 28, 2015. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.